Ludo Schropp

Ludo Schropp

Auto-generated profile, based on publicly available information

Ludo Schropp

Department of Vascular Surgery, University Medical Center Utrecht, Utrecht, the Netherlands

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 June 2022 in Journal of Thrombosis and Haemostasis
Verified
Journal Article
Open access
RKRobert J.C.M.F. de Kleijn
Robert J.C.M.F. de Kleijn
LSLudo Schropp
Ludo Schropp
EHEline S. van Hattum
Eline S. van Hattum
Çağdaş ÜnlüÇağdaş Ünlü
Çağdaş Ünlü
SMSaskia Middeldorp
Saskia Middeldorp
Gert Jan de BorstGert Jan de Borst
Gert Jan de Borst
Primary deep vein thrombosis of the upper extremity (UEDVT) is a rare condition but up to 60% of patients may develop post‐thrombotic syndrome in the upper extremity (UE‐PTS) with significant morbidity and decreased quality of life. However, there is no universally accepted method to diagnose and classify UE‐PTS, hampering scientific research on UEDVT treatment. Through this international Delphi consensus study we aimed to determine what a clinical score for diagnosing UE‐PTS should entail. An online focus group survey among 20 patients treated for UEDVT was performed to provide clinical parameters before the start of a four round electronic Delphi consensus study among 25 international experts. The CREDES recommendations on Conducting and Reporting Delphi Studies were applied. Open text questions, multiple selection questions, and 9‐point Likert scales were used. Consensus was set at 70% agreement. After four rounds, agreement was reached on a composite score of five symptoms and three clinical signs, combined with a functional disability score. The signs and symptom will each be scored on a severity scale of 0–3 and the total score expressed as an ordinal variable; no/mild/moderate/or severe PTS. The functional disability portion measures the impact of the signs and symptoms on the functionality of the patient’s arm. Consensus was reached on a composite score of signs and symptoms of UE‐PTS combined with a functional disability score. Clinical validation of the UE‐PTS score in a large patient cohort is mandatory to facilitate application in future research.

6 January 2023 in PLOS ONE
Verified
Journal Article
Open access
PDF file
LSLudo Schropp
Ludo Schropp
RKRobert J. C. M. F. de Kleijn
Robert J. C. M. F. de Kleijn
JWJan Westerink
Jan Westerink
MNMathilde Nijkeuter
Mathilde Nijkeuter
EVEvert-jan Vonken
Evert-jan Vonken
TCTrots Registry Collaborators
Trots Registry Collaborators
Introduction: There is a lack of comprehensive and uniform data on primary upper extremity deep venous thrombosis (pUEDVT). pUEDVT includes venous thoracic outlet syndrome related upper extremity deep venous thrombosis (UEDVT) and idiopathic UEDVT. Research on these conditions has been hampered by their rarity, lack of uniform diagnostic criteria, and heterogeneity in therapeutic strategies. To improve current research data collection using input of all various pUEDVT treating medical specialists, we initiated the ThoRacic OuTlet Syndrome (TROTS) registry. The aim of the TROTS registry is to a) collect extensive data on all pUEDVT patients through a predefined protocol, b) give insight in the long term outcome using patient reported outcome measures, c) create guidance in the diagnostic and clinical management of these conditions, and thereby d) help provide content for future research. Methods and analysis: The TROTS registry was designed as an international prospective longitudinal observational registry for data collection on pUEDVT patients. All pUEDVT patients, regardless of treatment received, can be included in the registry after informed consent is obtained. All relevant data regarding the initial presentation, diagnostics, treatment, and follow-up will be collected prospectively in an electronic case report form. In addition, a survey containing general questions, a Health-related Quality of Life questionnaire (EQ-5D-5L), and Functional Disability questionnaire (Quick-DASH) will be sent periodically (at the time of inclusion, one and two years after inclusion, and every five years after inclusion) to the participant. The registry protocol was approved by the Medical Ethical Review Board and registered in the Netherlands Trial Register under Trial-ID NL9680. The data generated by the registry will be used for future research on pUEDVT and published in peer reviewed journals. Conclusion: TROTS registry data will be used to further establish the optimal management of pUEDVT and lay the foundation for future research and guidelines.

24 May 2023 in Annals of Vascular Surgery
Verified
Journal Article
Open access
MKMert Kök
Mert Kök
LSLudo Schropp
Ludo Schropp
ISIrene C. van der Schaaf
Irene C. van der Schaaf
EVEvert-Jan Vonken
Evert-Jan Vonken
EHEline S. van Hattum
Eline S. van Hattum
BPBart-Jeroen Petri
Bart-Jeroen Petri
The optimal diagnostic and treatment algorithm for patients with suspected thoracic outlet syndrome (TOS) remains challenging. Botulinum toxin (BTX) muscle injections have been suggested to shrink muscles in the thoracic outlet reducing neurovascular compression. This systematic review evaluates the diagnostic and therapeutic value of BTX injections in TOS. A systematic review of studies reporting BTX as a diagnostic or therapeutic tool in TOS (or pectoralis minor syndrome (PMS) as TOS subtype) was conducted in PubMed, EMBASE, and CENTRAL databases on May 26th, 2022. The PRISMA statement was followed. Primary endpoint was symptom reduction after primary procedure. Secondary endpoints were symptom reduction after repeated procedures, the degree of symptom reduction, complications, and duration of clinical effect. Eight studies (one randomized controlled trial (RCT), one prospective cohort study, and six retrospective cohort studies) were included reporting 716 procedures in at least 497 patients (at minimum 350 primary and 25 repeated procedures, residual unclear) diagnosed with presumably only neurogenic TOS (NTOS). Except for the RCT, the methodological quality was fair to poor. All studies were designed on an intention to treat basis, one also investigated BTX as a diagnostic tool to differentiate PMS from costoclavicular compression. Reduction of symptoms was reported in 46-63% of primary procedures, no significant difference was found in the RCT. The effect of repeated procedures could not be determined. Degree of symptom reduction was reported by up to 30-42% on the Short-form McGill Pain scale and up to 40mm on a visual analogue scale. Complication rates varied among studies, no major complications were reported. Symptom relief ranged from one to six months. Based on limited quality evidence, BTX may provide short-lasting symptom relief in some NTOS patients but remains overall undecided. The role of BTX for treatment of vascular TOS and as a diagnostic tool in TOS is currently unexploited.

15 July 2025 in European Journal of Vascular and Endovascular Surgery
Verified
Journal Article
Open access
LSLudo Schropp
Ludo Schropp
EVEvert-jan Vonken
Evert-jan Vonken
MSMaarten L.J. Smits
Maarten L.J. Smits
EGEva K.L. de Graaf
Eva K.L. de Graaf
SGSanne E. Gillebaard
Sanne E. Gillebaard
Gert Jan de BorstGert Jan de Borst
Gert Jan de Borst
Diagnostic criteria for venous and arterial thoracic outlet syndrome (TOS) are heterogeneous. Detailed guidance on imaging methods and reporting is lacking. This study examined the reliability of a standardised method to quantify vascular compression in the thoracic outlet on dynamic computed tomography (CT) and magnetic resonance (MR) imaging. A standardised and pragmatic method to calculate changes in area using the major and minor diameter of the subclavian artery and vein in the sagittal plane during adduction and abduction was investigated. In a single TOS expertise centre, all CT and MR scans performed according to the TOS protocol were retrospectively identified and independently analysed by four observers using the pre-defined measurement method. Intraclass correlation coefficients were calculated to assess inter- and intra-observer reliability, with thresholds of < 0.5 (poor), 0.5 - 0.75 (moderate), > 0.75 - 0.9 (good), and > 0.9 (excellent). Fifty one CT scans (102 arms) and 58 MR scans (116 arms) were analysed. Venous compression (> 50%) was more prevalent compared with arterial compression both in the CT (51% vs. 16%) and MR (64% vs. 2%) cohorts. Inter-observer agreement for CT measurements was 0.79 (95% confidence interval [CI] 0.69 - 0.86) and 0.82 (95% CI 0.75 - 0.88) for arterial and venous compression, respectively; intra-observer agreement was 0.80 (95% CI 0.72 - 0.86) and 0.84 (95% CI 0.76 - 0.89). For MR measurements, inter-observer agreement was 0.36 (95% CI 0.16 - 0.53) and 0.38 (95% CI 0.20 - 0.54) for arterial and venous compression, respectively; intra-observer agreement was 0.39 (95% CI 0.23 - 0.54) and 0.60 (95% CI 0.47 - 0.71). The pre-defined measurement protocol applied on standard CT imaging proved reliable for both arterial and venous quantification of vascular compression. The same measurement protocol applied on MR imaging showed poor inter- and intra-observer reliability. Use of this standardised measurement protocol with CT in prospective multicentre studies on vascular TOS is advocated.

1 January 2022 in European Journal of Vascular and Endovascular Surgery
Verified
Journal Article
Open access
LSLudo Schropp
Ludo Schropp
RKRobert J.C.M.F. de Kleijn
Robert J.C.M.F. de Kleijn
EHEline S. van Hattum
Eline S. van Hattum
BPBart-Jeroen Petri
Bart-Jeroen Petri
EVEvert-jan Vonken
Evert-jan Vonken
Gert Jan de BorstGert Jan de Borst
Gert Jan de Borst

8 March 2022 in Journal of Endovascular Therapy
Verified
Journal Article
Closed access
LSLudo Schropp
Ludo Schropp
RKRobert J. C. M. F. de Kleijn
Robert J. C. M. F. de Kleijn
EVEvert-Jan Vonken
Evert-Jan Vonken
JLJorinde van Laanen
Jorinde van Laanen
JTJoep Teijink
Joep Teijink
GBGert J. de Borst
Gert J. de Borst
Purpose: The aim of this paper was to report our experience with arterial and venous endovascular stent placement in the thoracic outlet (TO) and review available literature. Methods: All patients that underwent arterial or venous stent placement in the TO between 2013 and 2020 in 5 Dutch vascular teaching-hospitals were retrospectively identified. Primary endpoint was symptomatic stent failure due to stenosis, chronic or posture dependent compression, fracture, or occlusion of the stent. Secondary endpoints were symptoms at last follow-up and re-interventions. For the literature review, we searched studies reporting on stenting in the TO. Results: Twenty-six patients were included with 11 arterial and 15 venous stents implanted to treat angioplasty resistant stenosis in arterial or venous TO syndrome, iatrogenic or traumatic vascular injury, radiotherapy fibrosis, or arterial dissection. Median follow-up was 19 and 14 months in the arterial and venous-group, respectively. Eight (73%) patients in the arterial, and 9 (60%) in the venous-group suffered symptomatic stent failure. Seven (64%) patients in the arterial, and 9 (60%) in the venous-group required at least 1 re-intervention. When comparing all patients with stent placement after TO decompression (TOD) to patients without, there were substantially more symptomatic stent failures and re-interventions required in the patients without TOD. Six patients (54%) in the arterial-group and 11 (73%) in the venous-group were symptom-free at last follow-up. Five articles describing 51 patients with arterial and 6 articles describing 81 patients with venous stents were included in the literature review. In the arterial-group, no TOD prior to stent placement was performed, while in the venous-group all but 1 article performed TOD prior to stent placement. Results showed comparable rates of symptomatic stent failure (24% vs 30%), and patients requiring re-interventions (29% vs 21%) between groups. Conclusion: Based on our multicenter series and review, stents in the TO have a considerable risk of failure, both in the venous and the arterial territory. Especially in patients without TOD: the need for re-interventions is high and half the patients eventually undergo TOD. Based on the currently available data, stenting in the TO should be applied cautiously while TOD should be considered.